Ali Al-Husry Buys 50,000 Shares of Hikma Pharmaceuticals Plc (HIK) Stock
Hikma Pharmaceuticals Plc (LON:HIK) insider Ali Al-Husry bought 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 27th. The stock was acquired at an average cost of GBX 2,094 ($27.33) per share, with a total value of £1,047,000 ($1,366,662.32).
Ali Al-Husry also recently made the following trade(s):
- On Friday, September 23rd, Ali Al-Husry bought 50,000 shares of Hikma Pharmaceuticals Plc stock. The stock was acquired at an average cost of GBX 2,099 ($27.40) per share, with a total value of £1,049,500 ($1,369,925.60).
- On Wednesday, September 21st, Ali Al-Husry bought 50,000 shares of Hikma Pharmaceuticals Plc stock. The stock was acquired at an average cost of GBX 2,138 ($27.91) per share, with a total value of £1,069,000 ($1,395,379.19).
Hikma Pharmaceuticals Plc (LON:HIK) opened at 2049.00 on Friday. The company’s market capitalization is GBX 4.63 billion. Hikma Pharmaceuticals Plc has a 52-week low of GBX 1,575.00 and a 52-week high of GBX 2,703.00. The company’s 50-day moving average is GBX 2,176.69 and its 200-day moving average is GBX 2,245.79.
A number of research analysts recently weighed in on HIK shares. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Hikma Pharmaceuticals Plc in a research report on Friday, September 23rd. Barclays PLC reiterated an “overweight” rating and issued a GBX 2,900 ($37.85) price target on shares of Hikma Pharmaceuticals Plc in a research note on Friday, September 9th. Numis Securities Ltd reiterated a “hold” rating and issued a GBX 2,660 ($34.72) price target on shares of Hikma Pharmaceuticals Plc in a research note on Wednesday, August 24th. Jefferies Group cut their price target on shares of Hikma Pharmaceuticals Plc from GBX 2,990 ($39.03) to GBX 2,500 ($32.63) and set a “buy” rating for the company in a research note on Monday, September 12th. Finally, Citigroup Inc. cut shares of Hikma Pharmaceuticals Plc to a “neutral” rating and set a GBX 2,600 ($33.94) price target for the company. in a research note on Thursday, August 4th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of GBX 2,520.90 ($32.91).
About Hikma Pharmaceuticals Plc
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe.
Receive News & Stock Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related stocks with our FREE daily email newsletter.